Morgan Stanley’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-14,836
| Closed | -$44K | – | 6662 |
|
|
2016
Q3 | $44K | Sell |
14,836
-36,665
| -71% | -$63.5K | ﹤0.01% | 5642 |
|
|
2016
Q2 | $77K | Sell |
51,501
-223,233
| -81% | -$511K | ﹤0.01% | 5367 |
|
|
2016
Q1 | $1.02M | Sell |
274,734
-562,453
| -67% | -$3.48M | ﹤0.01% | 3929 |
|
|
2015
Q4 | $8.46M | Sell |
837,187
-255,927
| -23% | -$3.08M | ﹤0.01% | 2142 |
|
|
2015
Q3 | $14.9M | Buy |
1,093,114
+363,111
| +50% | +$6.47M | 0.01% | 1630 |
|
|
2015
Q2 | $13.8M | Buy |
730,003
+379,967
| +109% | +$8.22M | ﹤0.01% | 1811 |
|
|
2015
Q1 | $9.16M | Sell |
350,036
-215,621
| -38% | -$5.49M | ﹤0.01% | 2138 |
|
|
2014
Q4 | $11.8M | Buy |
565,657
+58,479
| +12% | +$1.47M | ﹤0.01% | 1909 |
|
|
2014
Q3 | $16.9M | Buy |
507,178
+445,355
| +720% | +$13.8M | 0.01% | 1568 |
|
|
2014
Q2 | $1.99M | Buy |
61,823
+2,034
| +3% | +$75.7K | ﹤0.01% | 3487 |
|
|
2014
Q1 | $2.76M | Sell |
59,789
-129,129
| -68% | -$7.57M | ﹤0.01% | 3144 |
|
|
2013
Q4 | $13.4M | Buy |
188,918
+1,122
| +0.6% | +$85.8K | 0.01% | 1675 |
|
|
2013
Q3 | $16.1M | Sell |
187,796
-13,690
| -7% | -$1.16M | 0.01% | 1402 |
|
|
2013
Q2 | $12.8M | Buy |
+201,486
| New | +$10.7M | 0.01% | 1501 |
|
Morgan Stanley's AEGR Position: Q4 2016 in Review
Morgan Stanley sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 14,836 shares — an estimated $44K sold.
Morgan Stanley first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $16.9M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Morgan Stanley reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Morgan Stanley sold 14,836 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $44K.
- Morgan Stanley first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Morgan Stanley's Aegerion Pharmaceuticals position peaked at $16.9M in Q3 2014.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.